Enveric Biosciences (ENVB) Net Margin (2014 - 2020)
Enveric Biosciences (ENVB) posted Net Margin of 12.62% for Q3 2020, up 38.03% sequentially from 20.37% in Q2 2020, and down 1191.0% YoY from 1.16% in Q4 2019.
Enveric Biosciences (ENVB) Net Margin (2014 - 2020) Analysis & Trends
Enveric Biosciences has reported Net Margin for 7 years, with the latest figure at 12.62% in Q3 2020.
- Quarterly Net Margin fell 1191.0% year-over-year to 12.62% in Q3 2020, while the trailing twelve-month figure through Sep 2020 was 20.57% (up 3598.0% YoY) and the FY2019 annual result came in at 15.12%, up 3019.0% from the prior year.
- Net Margin improved to 12.62% in Q3 2020 per ENVB's latest filing, from 20.37% in the prior quarter.
- Over five years, Net Margin peaked at 36.71% in Q3 2018 and troughed at 193.23% in Q4 2018.
- A 5-year average of 22.81% and a median of 17.67% in 2016 frame the typical range for Net Margin.
- The sharpest annual moves came in 2018 and 2019: Net Margin tumbled 17971 bps in 2018, then surged 16411 bps in 2019.
- Over 5 years, Net Margin stood at 10.51% in 2016, then sank by 229 bps to 13.52% in 2017, then tumbled by 1330 bps to 193.23% in 2018, then jumped by 85 bps to 29.12% in 2019, then surged by 57 bps to 12.62% in 2020.
- According to Business Quant data, Net Margin over the past three periods registered 12.62%, 20.37%, and 19.71% for Q3 2020, Q2 2020, and Q1 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | -12.62% |
| Jun 30, 2020 | -20.37% |
| Mar 31, 2020 | -19.71% |
| Dec 31, 2019 | -29.12% |
| Sep 30, 2019 | -0.72% |
| Jun 30, 2019 | -12.37% |
| Mar 31, 2019 | -18.39% |
| Dec 31, 2018 | -193.23% |
| Sep 30, 2018 | 36.71% |
| Jun 30, 2018 | -12.32% |
| Mar 31, 2018 | -19.25% |
| Dec 31, 2017 | -13.52% |
| Sep 30, 2017 | -36.79% |
| Jun 30, 2017 | -30.85% |
| Mar 31, 2017 | -9.90% |
| Dec 31, 2016 | 10.51% |
| Sep 30, 2016 | -17.67% |
| Jun 30, 2016 | -18.08% |
| Mar 31, 2016 | -15.65% |
| Dec 31, 2015 | -23.11% |